表紙
市場調查報告書

糖尿病治療藥的全球市場(2012年∼2024年)

Diabetes Care Drugs Market - Growth, Trends, and Forecasts (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 390670
出版日期 內容資訊 英文 150 Pages
商品交期: 2-3個工作天內
價格
糖尿病治療藥的全球市場(2012年∼2024年) Diabetes Care Drugs Market - Growth, Trends, and Forecasts (2020 - 2025)
出版日期: 2020年08月01日內容資訊: 英文 150 Pages
簡介

2017年的全球糖尿病治療藥市場市場規模達到675億1,043萬美元,預計從2019年到2024年這段預測期間內,將以5.65%的年複合成長率成長。

本報告提供全球糖尿病治療藥市場調查,整體市場趨勢,各治療藥、地區的詳細趨勢,市場成長的影響要素分析,競爭情形,主要企業簡介等資訊總括性彙整。

目錄

第1章 簡介

  • 調查的成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 成長要素
  • 阻礙因素
  • 波特的五力分析
    • 賣主談判力
    • 買方議價能力
    • 新加入廠商的威脅
    • 替代產品及服務的威脅
    • 競爭的激烈程度

第5章 市場區隔

  • 各治療藥物(以金額、數量為準,2012年∼2024年)
    • 口服抗糖尿病藥物
    • 胰島素
    • 非胰島素注射劑
    • 複合治療藥
  • 地區
    • 北美
    • 歐洲
    • 南美
    • 亞太地區
    • 中東、非洲

第6章 市場指標

  • 第一型糖尿病人口(2012年∼2024年)
  • 第二型糖尿病人口(2012年∼2024年)

第7章 競爭情形

  • 企業簡介
    • Novo Nordisk
    • Sanofi
    • Eli Lilly
    • 武田藥品工業
    • Pfizer
    • Janssen Pharmaceuticals
    • Astellas Pharma Inc.
    • Boehringer Ingelheim
    • Merck and Co.
    • AstraZeneca
    • Bristol Myers Squibb
    • Novartis
  • 企業佔有率分析
    • Novo Nordisk
    • Sanofi
    • Eli Lilly
    • AstraZeneca
    • Astellas Pharma Inc.
    • Janssen Pharmaceuticals
    • Merck and Co.
    • 其他

第8章 市場機會及未來趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 55895

The diabetes care drugs market reached USD 69.7 billion in 2019, and it is anticipated to register a CAGR of over 4.5% during the forecast period (2020-2025).

  • The significant growth in the market can be attributed to factors, such as the rising prevalence of diabetes and the increasing number of programs initiated by various health organizations related to health awareness. Currently, about 10% of all diabetes cases are Type-1 and the remaining are of Type-2.
  • As of 2019, North America accounted for a major share in the market, followed by Asia-Pacific. The increase in the number of diabetes patients is primarily due to increasing obesity among people caused by unhealthy diets and sedentary lifestyles. The market in Asia-Pacific is mainly driven by increasing demand for diabetes drugs from China and India. Currently, China has over 120 million diabetes patients, while the number of diabetes patients in India is expected to reach 87 million by 2025.
  • Based on drugs, the insulin segment holds a significant share in the market. Over 100 million people around the world need insulin, including all the people suffering from Type-1 diabetes and between 10% and 25% of people with Type-2 diabetes.

Key Market Trends

Insulin Drugs Accounted for Almost 25% Market Share in the Diabetes Care drugs Market in 2019

The insulin segment is expected to increase with a CAGR of over 2.5% during the forecast period, mainly due to the demand from the Type-1 diabetes population, which was more than 30 million by the end of 2019. Some of the Type-2 patients also depend on insulin. Although only 10% of the diabetes population is Type-1, the intake of insulin is higher in them. Demand for insulin is driven by an increase in awareness about the benefits of insulin for diabetes patients, especially in emerging economies. Other factors, such as rapid development in insulin delivery systems, drug and analog development by major companies, and the rise in geriatric and obese population, may fuel the growth of the insulin market. In 2019, in the insulin drugs segment, basal insulin accounted for 46% market share and more than 13% market share in the overall diabetes care drugs market. According to the International Diabetes Federation, diabetes patients spent USD 760 billion in 2019, of which, a major chunk was spent by Type-1 diabetes patients on insulin drugs.

North America and Asia-Pacific Together Accounted for More than 60% of the Market Share in 2019

North America recorded more than USD 29 billion in revenue in 2019, which is expected to further increase with a CAGR of more than 4% during the forecast period. This is primarily due to the increasing diabetes population in North America, due to stress, unhealthy diets, and obesity. In North America, there are more than 29 million diabetes patients, and this number is expected to increase to 32 million by 2025. The United States alone recorded over 25 million diabetes patients in 2019. In North America, the United States holds a major share in the diabetes care drugs market. The diabetes drug market growth in this region is also supported by favorable government reimbursement policies and advanced healthcare infrastructure. Countries in Southeast Asia are expected to generate higher demand in the coming years, primarily due to the initiatives undertaken by the local government and health organizations to spread awareness about diabetes, drugs, and devices. The diabetes population in this region has increased at an alarming rate over the past decade. The major challenge faced by the diabetes drugs market in the emerging economies of the Asia-Pacific region is the lack of healthcare infrastructure and centralized supply chains, which result in price variations.

Competitive Landscape

The diabetes drugs market is moderately fragmented, with few significant and generic players. The insulin drugs and Sglt-2 drugs market is dominated by few major players, like Novo-Nordisk, Sanofi, AstraZeneca, and Bristol Myers Squibb. The market for oral drugs, like Sulfonylureas and Meglitinides, comprises more generic players. The intensity of competition among the players is high, as each player is striving to develop new drugs and offer it at competitive pricing. Furthermore, in order to increase their market shares, players are tapping into new markets, especially the emerging economies where the demand is very high compared to the supply. Some of the recent developments in the diabetes care drugs market include:

  • In January 2020, the US FDA approved Trijardy XR (empagliflozin/linagliptin/metformin hydrochloride extended-release tablets) to lower blood sugar in adults with Type-2 diabetes. Trijardy XR provides three Type-2 diabetes medicines in one pill.
  • In September 2019, Novo Nordisk announced that the US FDA has approved Rybelsus (semaglutide) oral tablets for adult patients with Type-2 diabetes. With this approval, Rybelsus has become the first glucagon-like peptide (GLP-1) receptor protein treatment approved for use in the United States, which does not need to be injected.
  • In March 2019, Novo Nordisk announced its plan to invest about USD 98 million in upgrading and expanding the insulin drug manufacturing facility in Kalundborg, Denmark. The project is scheduled to be completed before the end of 2020.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
  • 4.3 Market Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Drugs
    • 5.1.1 Oral Anti-diabetic drugs (Value and Volume 2012-2025)
      • 5.1.1.1 Biguanides
      • 5.1.1.1.1 Metformin
      • 5.1.1.2 Alpha-glucosidase Inhibitors
      • 5.1.1.3 Dopamine -D2 Receptor Agonist
      • 5.1.1.3.1 Cycloset (Bromocriptin)
      • 5.1.1.4 Sodium-glucose Cotransport -2 (SGLT-2) Inhibitors
      • 5.1.1.4.1 Invokana (Canagliflozin)
      • 5.1.1.4.2 Jardiance (Empagliflozin)
      • 5.1.1.4.3 Farxiga/Forxiga (Dapagliflozin)
      • 5.1.1.4.4 Suglat (Ipragliflozin)
      • 5.1.1.5 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
      • 5.1.1.5.1 Januvia (Sitagliptin)
      • 5.1.1.5.2 Onglyza (Saxagliptin)
      • 5.1.1.5.3 Tradjenta (Linagliptin)
      • 5.1.1.5.4 Vipidia/Nesina (Alogliptin)
      • 5.1.1.5.5 Galvus (Vildagliptin)
      • 5.1.1.6 Sulfonylureas
      • 5.1.1.7 Meglitinides
    • 5.1.2 Insulin (Value and Volume 2012-2025)
      • 5.1.2.1 Basal or Long-acting Insulin
      • 5.1.2.1.1 Lantus (Insulin Glargine)
      • 5.1.2.1.2 Levemir (Insulin Detemir)
      • 5.1.2.1.3 Toujeo (Insulin Glargine)
      • 5.1.2.1.4 Tresiba (Insulin Degludec)
      • 5.1.2.1.5 Basaglar (Insulin Glargine)
      • 5.1.2.2 Bolus or Fast-acting Insulin
      • 5.1.2.2.1 NovoRapid/Novolog (Insulin Aspart)
      • 5.1.2.2.2 Humalog (Insulin Lispro)
      • 5.1.2.2.3 Apidra (Insulin Glulisine)
      • 5.1.2.3 Traditional Human Insulin
      • 5.1.2.3.1 Novolin/Actrapid/Insulatard
      • 5.1.2.3.2 Humulin
      • 5.1.2.3.3 Insuman
      • 5.1.2.4 Biosimilar Insulin
      • 5.1.2.4.1 Insulin Glargine Biosimilars
      • 5.1.2.4.2 Human Insulin Biosimilars
    • 5.1.3 Non-insulin Injectable Drug (Value and Volume 2012-2025)
      • 5.1.3.1 GLP-1 Receptor Agonists
      • 5.1.3.1.1 Victoza (Liraglutide)
      • 5.1.3.1.2 Byetta (Exenatide)
      • 5.1.3.1.3 Bydureon (Exenatide)
      • 5.1.3.1.4 Trulicity (Dulaglutide)
      • 5.1.3.1.5 Lyxumia (Lixisenatide)
      • 5.1.3.2 Amylin Analogue
      • 5.1.3.2.1 Symlin (Pramlintide)
    • 5.1.4 Combination Drug
      • 5.1.4.1 Combination Insulin
      • 5.1.4.1.1 NovoMix (Biphasic Insulin Aspart)
      • 5.1.4.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
      • 5.1.4.1.3 Xultophy (Insulin Degludec and Liraglutide)
      • 5.1.4.2 Oral Combination
      • 5.1.4.2.1 Janumet (Sitagliptin and Metformin HCl)
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States (Value and Volume 2012-2025)
      • 5.2.1.1.1 Oral Anti-diabetic Drugs
      • 5.2.1.1.2 Insulin
      • 5.2.1.1.3 Non-insulin Injectable Drugs
      • 5.2.1.1.4 Combination Drugs
      • 5.2.1.2 Canada (Value and Volume 2012-2025)
      • 5.2.1.2.1 Oral Anti-diabetic Drugs
      • 5.2.1.2.2 Insulin
      • 5.2.1.2.3 Non-insulin Injectable Drugs
      • 5.2.1.2.4 Combination Drugs
      • 5.2.1.3 Rest of North America (Value and Volume 2012-2025)
      • 5.2.1.3.1 Oral Anti-diabetic Drugs
      • 5.2.1.3.2 Insulin
      • 5.2.1.3.3 Non-insulin Injectable Drugs
      • 5.2.1.3.4 Combination Drugs
    • 5.2.2 Europe
      • 5.2.2.1 France (Value and Volume 2012-2025)
      • 5.2.2.1.1 Oral Anti-diabetic Drugs
      • 5.2.2.1.2 Insulin
      • 5.2.2.1.3 Non-insulin Injectable Drugs
      • 5.2.2.1.4 Combination Drugs
      • 5.2.2.2 Germany (Value and Volume 2012-2025)
      • 5.2.2.2.1 Oral Anti-diabetic Drugs
      • 5.2.2.2.2 Insulin
      • 5.2.2.2.3 Non-insulin Injectable Drugs
      • 5.2.2.2.4 Combination Drugs
      • 5.2.2.3 Italy (Value and Volume 2012-2025)
      • 5.2.2.3.1 Oral Anti-diabetic Drugs
      • 5.2.2.3.2 Insulin
      • 5.2.2.3.3 Non-insulin Injectable Drugs
      • 5.2.2.3.4 Combination Drugs
      • 5.2.2.4 Spain (Value and Volume 2012-2025)
      • 5.2.2.4.1 Oral Anti-diabetic Drugs
      • 5.2.2.4.2 Insulin
      • 5.2.2.4.3 Non-insulin Injectable Drugs
      • 5.2.2.4.4 Combination Drugs
      • 5.2.2.5 United Kingdom (Value and Volume 2012-2025)
      • 5.2.2.5.1 Oral Anti-diabetic Drugs
      • 5.2.2.5.2 Insulin
      • 5.2.2.5.3 Non-insulin Injectable Drugs
      • 5.2.2.5.4 Combination Drugs
      • 5.2.2.6 Russia (Value and Volume 2012-2025)
      • 5.2.2.6.1 Oral Anti-diabetic Drugs
      • 5.2.2.6.2 Insulin
      • 5.2.2.6.3 Non-insulin Injectable Drugs
      • 5.2.2.6.4 Combination Drugs
      • 5.2.2.7 Rest of Europe (Value and Volume 2012-2025)
      • 5.2.2.7.1 Oral Anti-diabetic Drugs
      • 5.2.2.7.2 Insulin
      • 5.2.2.7.3 Non-insulin Injectable Drugs
      • 5.2.2.7.4 Combination Drugs
    • 5.2.3 Latin America
      • 5.2.3.1 Mexico (Value and Volume 2012-2025)
      • 5.2.3.1.1 Oral Anti-diabetic Drugs
      • 5.2.3.1.2 Insulin
      • 5.2.3.1.3 Non-insulin Injectable Drugs
      • 5.2.3.1.4 Combination Drugs
      • 5.2.3.2 Brazil (Value and Volume 2012-2025)
      • 5.2.3.2.1 Oral Anti-diabetic Drugs
      • 5.2.3.2.2 Insulin
      • 5.2.3.2.3 Non-insulin Injectable Drugs
      • 5.2.3.2.4 Combination Drugs
      • 5.2.3.3 Rest of Latin America (Value and Volume 2012-2025)
      • 5.2.3.3.1 Oral Anti-diabetic Drugs
      • 5.2.3.3.2 Insulin
      • 5.2.3.3.3 Non-insulin Injectable Drugs
      • 5.2.3.3.4 Combination Drugs
    • 5.2.4 Asia-Pacific
      • 5.2.4.1 Japan (Value and Volume 2012-2025)
      • 5.2.4.1.1 Oral Anti-diabetic Drugs
      • 5.2.4.1.2 Insulin
      • 5.2.4.1.3 Non-insulin Injectable Drugs
      • 5.2.4.1.4 Combination Drugs
      • 5.2.4.2 South Korea (Value and Volume 2012-2025)
      • 5.2.4.2.1 Oral Anti-diabetic Drugs
      • 5.2.4.2.2 Insulin
      • 5.2.4.2.3 Non-insulin Injectable Drugs
      • 5.2.4.2.4 Combination Drugs
      • 5.2.4.3 China (Value and Volume 2012-2025)
      • 5.2.4.3.1 Oral Anti-diabetic Drugs
      • 5.2.4.3.2 Insulin
      • 5.2.4.3.3 Non-insulin Injectable Drugs
      • 5.2.4.3.4 Combination Drugs
      • 5.2.4.4 India (Value and Volume 2012-2025)
      • 5.2.4.4.1 Oral Anti-diabetic Drugs
      • 5.2.4.4.2 Insulin
      • 5.2.4.4.3 Non-insulin Injectable Drugs
      • 5.2.4.4.4 Combination Drugs
      • 5.2.4.5 Australia (Value and Volume 2012-2025)
      • 5.2.4.5.1 Oral Anti-diabetic Drugs
      • 5.2.4.5.2 Insulin
      • 5.2.4.5.3 Non-insulin Injectable Drugs
      • 5.2.4.5.4 Combination Drugs
      • 5.2.4.6 Vietnam (Value and Volume 2012-2025)
      • 5.2.4.6.1 Oral Anti-diabetic Drugs
      • 5.2.4.6.2 Insulin
      • 5.2.4.6.3 Non-insulin Injectable Drugs
      • 5.2.4.6.4 Combination Drugs
      • 5.2.4.7 Malaysia (Value and Volume 2012-2025)
      • 5.2.4.7.1 Oral Anti-diabetic Drugs
      • 5.2.4.7.2 Insulin
      • 5.2.4.7.3 Non-insulin Injectable Drugs
      • 5.2.4.7.4 Combination Drugs
      • 5.2.4.8 Indonesia (Value and Volume 2012-2025)
      • 5.2.4.8.1 Oral Anti-diabetic Drugs
      • 5.2.4.8.2 Insulin
      • 5.2.4.8.3 Non-insulin Injectable Drugs
      • 5.2.4.8.4 Combination Drugs
      • 5.2.4.9 Philippines (Value and Volume 2012-2025)
      • 5.2.4.9.1 Oral Anti-diabetic Drugs
      • 5.2.4.9.2 Insulin
      • 5.2.4.9.3 Non-insulin Injectable Drugs
      • 5.2.4.9.4 Combination Drugs
      • 5.2.4.10 Thailand (Value and Volume 2012-2025)
      • 5.2.4.10.1 Oral Anti-diabetic Drugs
      • 5.2.4.10.2 Insulin
      • 5.2.4.10.3 Non-insulin Injectable Drugs
      • 5.2.4.10.4 Combination Drugs
      • 5.2.4.11 Rest of Asia-Pacific (Value and Volume 2012-2025)
      • 5.2.4.11.1 Oral Anti-diabetic Drugs
      • 5.2.4.11.2 Insulin
      • 5.2.4.11.3 Non-insulin Injectable Drugs
      • 5.2.4.11.4 Combination Drugs
    • 5.2.5 Middle-East and Africa
      • 5.2.5.1 Saudi Arabia (Value and Volume 2012-2025)
      • 5.2.5.1.1 Oral Anti-diabetic Drugs
      • 5.2.5.1.2 Insulin
      • 5.2.5.1.3 Non-insulin Injectable Drugs
      • 5.2.5.1.4 Combination Drugs
      • 5.2.5.2 Iran (Value and Volume 2012-2025)
      • 5.2.5.2.1 Oral Anti-diabetic Drugs
      • 5.2.5.2.2 Insulin
      • 5.2.5.2.3 Non-insulin Injectable Drugs
      • 5.2.5.2.4 Combination Drugs
      • 5.2.5.3 Egypt (Value and Volume 2012-2025)
      • 5.2.5.3.1 Oral Anti-diabetic Drugs
      • 5.2.5.3.2 Insulin
      • 5.2.5.3.3 Non-insulin Injectable Drugs
      • 5.2.5.3.4 Combination Drugs
      • 5.2.5.4 Oman (Value and Volume 2012-2025)
      • 5.2.5.4.1 Oral Anti-diabetic Drugs
      • 5.2.5.4.2 Insulin
      • 5.2.5.4.3 Non-insulin Injectable Drugs
      • 5.2.5.4.4 Combination Drugs
      • 5.2.5.5 South Africa (Value and Volume 2012-2025)
      • 5.2.5.5.1 Oral Anti-diabetic Drugs
      • 5.2.5.5.2 Insulin
      • 5.2.5.5.3 Non-insulin Injectable Drugs
      • 5.2.5.5.4 Combination Drugs
      • 5.2.5.6 Rest of Middle-East and Africa (Value and Volume 2012-2025)
      • 5.2.5.6.1 Oral Anti-diabetic Drugs
      • 5.2.5.6.2 Insulin
      • 5.2.5.6.3 Non-insulin Injectable Drugs
      • 5.2.5.6.4 Combination Drugs

6 MARKET INDICATORS

  • 6.1 Type-1 Diabetes Population (2012-2025)
  • 6.2 Type-2 Diabetes Population (2012-2025)

7 COMPETITIVE LANDSCAPE

  • 7.1 Vendor Market Share
  • 7.2 Company Profiles
    • 7.2.1 Novo Nordisk
    • 7.2.2 Sanofi
    • 7.2.3 Eli Lilly and Company
    • 7.2.4 Biocon
    • 7.2.5 AstraZeneca
    • 7.2.6 Bristol Myers Squibb
    • 7.2.7 Boehringer Ingelheim
    • 7.2.8 Mylan
    • 7.2.9 Pfizer
    • 7.2.10 Johnson & Johnson
    • 7.2.11 Merck & Co.
    • 7.2.12 Novartis
    • 7.2.13 Astellas Pharma
    • 7.2.14 Teva Pharmaceuticals

8 MARKET OPPORTUNITIES AND FUTURE TRENDS